301
Views
5
CrossRef citations to date
0
Altmetric
ONCOLOGY

CD44 as a molecular marker to screen cancer stem cells in hypopharyngeal cancer

, , , , &
Pages 1219-1226 | Received 28 Mar 2013, Accepted 27 May 2013, Published online: 09 Jul 2013
 

Abstract

Conclusions: The CD44+ cells have a stronger proliferative capacity and higher tumorigenic potential than the CD44 cells, which suggests that the cancer stem cells of hypopharyngeal cancer may exist in the CD44+ tumor cell population. Therefore, we propose that CD44 is an important biological marker to screen cancer stem cells of hypopharyngeal cancer. Objectives: To study the significance of CD44 as a molecular marker for screening cancer stem cells in hypopharyngeal cancer. Methods: The CD44 expression levels in the hypopharyngeal cancer cell line FaDu were analyzed using flow cytometry. To investigate the biological significance of the CD44+ population, we sorted the CD44+ and CD44 cell populations by using magnetic-associated cell sorting (MACS) technology. After the separation, the purity of the CD44+ cells was determined using flow cytometry. The MTT method was used to detect the different proliferation capabilities of the CD44+ and CD44 cells in vitro. The tumorigenicity of the CD44+ and CD44 cells was determined by injecting CD44+ or CD44 cells (1 × 106 and 1 × 105) into the body of NOD/SCID mice. Results: Some (21.1 ± 1.56)% of the hypopharyngeal cancer cell line FaDu cells expressed CD44. The CD44+ population was efficiently sorted by MACS, and after separation, the purity of the CD44+ cells was (99.4 ± 0.29)%. The MTT assay indicated that the sorted CD44+ cells had a stronger proliferative capacity than the CD44 cells. The tumorigenicity study showed that all the mice injected with 1 × 106 CD44+ cells developed tumors (8/8), half the mice injected with 1 × 106 CD44 cells developed tumors (4/8), 1 of the 8 mice injected with 1 × 105 CD44+ cells developed tumors (12.5%), but none of the mice injected with 1 × 105 CD44 cells developed any tumors (0/8). At the same concentration, the difference in tumorigenic rates between the CD44+ and CD44 groups was statistically significant (Fisher's exact test, p < 0.05). Furthermore, the CD44+ group had a shorter incubation period than the CD44 group. In addition, the average tumor volume of the CD44+ group was (2017.81 ± 538.50) mm3; however, the average tumor volume of the CD44 group was (1153.25 ± 503.18) mm3. The difference was statistically significant (t = 2.67, p < 0.05).

Acknowledgments

Mingliang Xiang was the director of this research and in charge of funds. Chenling Shen contributed to laboratory experiments and wrote the manuscript. The study was supported by the National Natural Science Foundation of China, no. 81271088; and the Natural Science Foundation of Shanghai, no. 11ZR1423600.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.